Clinical Trials Logo

Clinical Trial Summary

The goal of this prospective randomized controlled study is to explore the role of indocyanine green-fluorescence imaging in management of cystic lymphatic malformation.. To clarify the application value of indocyanine green-fluorescence imaging in both diagnosis and treatment of cystic lymphatic malformation (cLM) in children, is helpful for exploring pathogenesis of cLM, and providing a clearer scientific basis for subsequent surgical intervention. It also provides alternative for the future diagnosis and treatment of cLM. Participants will receive indocyanine green-fluorescence imaging before operation, while the patients in control group will receive traditional operation. Researchers will compare difference in curative effect between two groups.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06275022
Study type Interventional
Source Nanjing Children's Hospital
Contact Tao Han, Dr.
Phone +86 186 5190 3495
Email dr.hantao@njmu.edu.cn
Status Recruiting
Phase N/A
Start date January 1, 2023
Completion date June 30, 2026

See also
  Status Clinical Trial Phase
Withdrawn NCT04994002 - A Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of CERC-006 in Adults With Complex Lymphatic Malformations Phase 1
Recruiting NCT05871970 - Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age Phase 2
Terminated NCT04409145 - First in Human Trial of Topical VT30 in Pts With Venous/Lymphatic Malformations Assoc With PIK3CA or TEK Gene Mutations Phase 1/Phase 2
Recruiting NCT03972592 - Topical Sirolimus in Cutaneous Lymphatic Malformations Phase 2
Recruiting NCT03243019 - Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations Phase 2
Recruiting NCT02399527 - Lymphatic Anomalies Registry for the Assessment of Outcome Data
Completed NCT06257719 - Clinical Characteristics of Lymphatic Malformations
Recruiting NCT04861064 - Weekly Sirolimus Therapy Phase 2
Recruiting NCT05563831 - National Evaluation of Patients With PIK3CA-Related Overgrowth Spectrum (PROS)
Completed NCT04836884 - Vascular Anomaly Pathology and Genomics Biopsy Study N/A
Not yet recruiting NCT05983159 - A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations Phase 2